We’ve successfully completed more Human Abuse Potential (HAP) protocols & published more HAP studies than any other CRO.
About Human Abuse Potential (HAP) studies
The increased attention to abuse potential in new drugs has created a complex regulatory landscape for Human Abuse Potential (HAP) studies.
The assessment of abuse potential is an important step in the drug development process and requires a proactive approach, customized for each compound. PRA partners with clients who are developing CNS compounds in order to incorporate critical regulatory decisions and requirements into their clinical development programs as early as possible. Learn more about the fundamentals of Human Abuse Potential studies with this 7-point checklist.
PRA’s scientific and clinical experts have delivered comprehensive HAP services for years, providing clients with the innovative solutions necessary to fully test their products. We conduct all of our studies at our comprehensive Phase 1 facilities in Salt Lake City, UT, Lenexa, KS and Groningen, The Netherlands.
Hepatic Impairment Studies – Early Patient Solutions
PRA Health Sciences’ Early Patient Solutions (EPS) is an established team of highly experienced Phase I professionals dedicated to early phase…
Accelerated Early Clinical Manufacturing
PRA’s Accelerated Early Clinical Manufacturing services provide on-site IMP development and manufacturing, as well as in-house Quality Control lab…
Renal Impairment Studies — Early Patient Solutions
PRA Health Sciences’ Early Development Services (EDS) has established a team dedicated to early phase patient studies. Our Early Patient Solutions…